Wirksamkeit von Atenativ bei Patienten mit angeborenem Antithrombinmangel, die sich einer Operation oder Entbindung unterziehen
Eine multizentrische, prospektive, offene, unkontrollierte Phase-3-Studie zur Bewertung der Wirksamkeit, Sicherheit und Pharmakokinetik von Atenativ bei Patienten mit angeborenem Antithrombinmangel, die sich einer Operation oder Entbindung unterziehen
The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Sigurd Knaub
- Telefonnummer: +41554512141
- E-Mail: Sigurd.Knaub@octapharma.com
Studienorte
-
-
-
Yerevan, Armenien
- Rekrutierung
- Yeolyan Hematology and Oncology Centre
-
-
-
-
-
Berlin, Deutschland
- Rekrutierung
- Vivantes Klinikum Friedrichshain Klinik für Angiologie Hämostaseologie
-
Bonn, Deutschland
- Rekrutierung
- UKB Bonn Institut für Experimentelle Hämatologie und Transfusionsmedizin
-
Duisburg, Deutschland
- Rekrutierung
- Gerinnungszentrum Rhein-Ruhr
-
-
-
-
-
Bron, Frankreich
- Rekrutierung
- Centre de Référence de l'Hémophilie Unité d'Hémostase Clinique Hôpital Cardiologique Louis Pradel
-
Reims, Frankreich
- Rekrutierung
- University Hospital of Reims
-
Rouen, Frankreich
- Rekrutierung
- Centre Hospitalier Universitaire de Rouen (CHU de Rouen) - Centre de Traitement des Maladies Hemorragiques (CRTH) (Centre d'Hemophiles)
-
-
-
-
-
Tbilisi, Georgia
- Rekrutierung
- Aversi Clinic
-
-
-
-
-
Petah Tikva, Israel
- Rekrutierung
- Rabin Medical Centre, Institute of Haematology
-
Ramat Gan, Israel
- Rekrutierung
- Sheba Medical Centre
-
-
-
-
-
Bergamo, Italien, 24127
- Rekrutierung
- Unita Strutturale Complessa di Immunoematologia e Medicina Trasfusionale -Dipartimento Interaziendale di Medicina Trasfusionale ed Ematologia - ASST Papa Giovanni XXIII ematologia Piazza OMS, 1
-
Milan, Italien
- Rekrutierung
- Universita degli Studi di Milano - IRCCS Ospedale Maggiore Policlinico - Centro Emofilia e Trombosi Angelo Bianchi Bonomi
-
Padua, Italien
- Rekrutierung
- University of Padua Medical School
-
Roma, Italien
- Rekrutierung
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
-
-
-
-
Craiova, Rumänien
- Rekrutierung
- Emergency County Hospital Craiova
-
-
-
-
-
Belgrade, Serbien
- Rekrutierung
- Clinical Center of Serbia
-
-
-
-
-
Madrid, Spanien, 28046
- Rekrutierung
- Hospital Universitario La Paz
-
Murcia, Spanien
- Rekrutierung
- Hospital Universitario Morales Meseguer
-
Ourense, Spanien, 32005
- Rekrutierung
- Ourense University Hospital
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Spanien, 33011
- Rekrutierung
- Central University Hospital of Asturias
-
-
-
-
-
Nymburk, Tschechien
- Rekrutierung
- Centre for Thrombosis and Haemaostasis Nemocnice
-
-
-
-
-
Debrecen, Ungarn
- Rekrutierung
- University of Debrecen, Medical and Health Science Centre
-
-
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20057
- Rekrutierung
- Georgetown University Hospital
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33124
- Rekrutierung
- University of Miami, Miller School of Medicine
-
-
Illinois
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Rekrutierung
- Bleeding and Clotting Disorders Institute
-
-
New York
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Weill Cornell Medicine, New York Presbyterian Hospital
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27708
- Rekrutierung
- Duke University School of Medicine, Division of Hematology
-
-
-
-
-
London, Vereinigtes Königreich
- Rekrutierung
- Royal-free Hospital-Katherine Dormandy Haemophilia and Thrombosis Centre
-
London, Vereinigtes Königreich
- Rekrutierung
- St. Thomas Hospital, Guy's and St. Thomas' NHS Foundation Trust
-
-
-
-
-
Vienna, Österreich
- Rekrutierung
- Medizinische Universität Wien. Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie und Hämostaseologie
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adult male or female patients ≥18 and ≤80 years of age. Solely in the US, 4 male or female patients between ≥12 and <17 years of age will be enrolled into the PK phase, and subsequently in the treatment phase, if applicable
- Documented congenital antithrombin deficiency, defined by plasma activity level of antithrombin ≤60% from medical history
- Personal or family history of TEs or TEEs (except for PK patients)
- For the Treatment Phase: either a) non-pregnant surgical patients scheduled for elective surgical procedure(s) known to be associated with a high risk for occurrence of TEs or TEEs, or b) pregnant patients of at least 27 weeks gestational age who are scheduled for caesarean section or delivery
- For female patients of childbearing potential entering the PK Phase who are not known to be pregnant, and for female surgical patients of childbearing potential entering the Treatment Phase for any procedure other than caesarean section or delivery, a negative urine pregnancy test at screening and at baseline
- Patient has provided informed consent
Exclusion Criteria:
-
Requires emergency surgery or emergency caesarean section
-
Has undergone surgery within the last 6 weeks
-
History or suspicion of another hereditary thrombophilic disorder other than antithrombin deficiency (e.g., activated protein C [APC] resistance/Factor V Leiden, Protein S or C deficiency, prothrombin gene mutation [G20210A], or acquired [lupus anticoagulant] thrombophilic disorder)
-
Malignancies, renal failure (patients on renal replacement therapy), or severe liver disease (aspartate aminotransferase [ASAT] >5 times the upper limit of normal)
-
Body mass index >40 kg/m2 (for non-pregnant patients, only)
-
Known hypersensitivity or allergic reaction to antithrombin or any of the excipients in Atenativ
-
History of anaphylactic reaction(s) to blood or blood components
-
Refusal to receive transfusion of blood-derived products
-
Administration of any antithrombin concentrate or antithrombin-containing blood product within 14 days of either of the two phases of the study
-
Prior diagnosis of heparin-induced thrombocytopenia
-
TE or TEE within the last 6 months
-
Female patients who are nursing at the time of screening*
-
Have participated in another investigational study within the last 30 days
-
Persons dependent on the sponsor, the investigator or the centre of investigation
-
Persons placed in an institution by administrative or judicial order
- criterion does not include female patients who plan to breastfeed after giving birth
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Atenativ treatment
During the PK phase, patients will receive a 60 IU/kg Atenativ as a single intravenous infusion for PK analysis. During the treatment phase, patients will receive a single intravenous loading dose followed by maintenance doses administered every 24 hours for approximately 2-7 days for surgical patients and approximately 5 days for parturients |
Antithrombin concentrate |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Thrombotic event incidence
Zeitfenster: Up to day 30 post treatment initiation
|
The primary objective of this study is to assess the incidence of the composite of TEs and TEEs in patients with congenital antithrombin deficiency under cover of Atenativ for surgical procedures or parturition |
Up to day 30 post treatment initiation
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Single dose Pharmacokinetics of Atenativ: Area under the curve (AUCnorm(0-∞))
Zeitfenster: Up to day 14 post PK infusion
|
Assess the area under the curve (AUCnorm(0-∞)) of Atenativ in patients with congenital antithrombin deficiency |
Up to day 14 post PK infusion
|
|
Single dose Pharmacokinetics of Atenativ: Maximum plasma concentration (Cmax)
Zeitfenster: Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
Assess the maximum plasma concentration (Cmax) after a single dose of Atenativ in patients with congenital antithrombin deficiency |
Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
|
Single dose Pharmacokinetics of Atenativ: Half-life (t1/2)
Zeitfenster: Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
Assess the half-life (t1/2) after a single dose of Atenativ in patients with congenital antithrombin deficiency |
Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
|
Single dose Pharmacokinetics of Atenativ: Mean residence time (MRT)
Zeitfenster: Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
Assess the mean residence time (MRT) after a single dose of Atenativ in patients with congenital antithrombin deficiency |
Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
|
Single dose Pharmacokinetics of Atenativ: Clearance (CL)
Zeitfenster: Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
Assess the clearance (CL) after a single dose of Atenativ in patients with congenital antithrombin deficiency |
Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
|
Single dose Pharmacokinetics of Atenativ: Incremental in vivo recovery (IVR)
Zeitfenster: Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
Assess the Incremental in vivo recovery after a single dose of Atenativ in patients with congenital antithrombin deficiency |
Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
|
Single dose Pharmacokinetics of Atenativ: Volume of distribution at steady state (Vss)
Zeitfenster: Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
Assess the volume of distribution at steady state (Vss) after a single dose of Atenativ in patients with congenital antithrombin deficiency |
Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
|
Single dose Pharmacokinetics of Atenativ: Maximum Plasma Concentration (Tmax)
Zeitfenster: Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
Assess the time to reach Maximum Plasma Concentration (Tmax) after a single dose of Atenativ in patients with congenital antithrombin deficiency |
Before first infusion, 20 minutes, 1 hour, 3 hours, 8 hrs, 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days, 8 days, 10 days, 12 days and 14 days post-infusion
|
|
10. Coagulation parameters: Activated partial thromboplastin time [aPTT]
Zeitfenster: Up to day 7 post treatment initiation
|
Assess activated partial thromboplastin time [aPTT] in patients with congenital antithrombin deficiency undergoing surgical procedures or parturition |
Up to day 7 post treatment initiation
|
|
Coagulation parameters: Prothrombin time [PT]
Zeitfenster: Up to day 7 post treatment initiation
|
Assess prothrombin time [PT] in patients with congenital antithrombin deficiency undergoing surgical procedures or parturition |
Up to day 7 post treatment initiation
|
|
Coagulation parameters: International normalised ratio [INR]
Zeitfenster: Up to day 7 post treatment initiation
|
Assess international normalised ratio [INR] in patients with congenital antithrombin deficiency undergoing surgical procedures or parturition |
Up to day 7 post treatment initiation
|
|
Coagulation parameters: Fibrinogen level
Zeitfenster: Up to day 7 post treatment initiation
|
Assess fibrinogen in patients with congenital antithrombin deficiency undergoing surgical procedures or parturition |
Up to day 7 post treatment initiation
|
|
Safety and tolerability: Number of adverse events (AEs)
Zeitfenster: Up to day 30 post treatment initiation
|
Number of adverse events (AEs) following treatment with Atenativ in patients with congenital antithrombin deficiency |
Up to day 30 post treatment initiation
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- ATN-106
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .